Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milrinone in Congenital Diaphragmatic Hernia
NCT02951130Phase 2Completed
- Sponsor
- NICHD Neonatal Research Network
- Start
- Oct 2017
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in congenital diaphragmatic hernia (CDH) and persistent pulmonary hypertension of the newborn (PPHN) comparing Milrinone with Placebo (2 arms). Primary endpoint: Oxygenation Response at 24 hours. Started Oct 2017; status: completed.
02
Drugs
milrinone
03
Conditions
congenital diaphragmatic hernia (CDH)persistent pulmonary hypertension of the newborn (PPHN)
Beyond the preview
Go deeper on NCT02951130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02951130.